» Articles » PMID: 24945812

Acute Hepatitis C in HIV-1 Infected Japanese Cohort: Single Center Retrospective Cohort Study

Overview
Journal PLoS One
Date 2014 Jun 20
PMID 24945812
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: HCV co-infection is a poor prognostic factor in HIV-1-infected patients. Although the number of newly reported patients who show seroconversion is increasing, the clinical features are still unclear, especially in Asian countries.

Design: A single-center retrospective cohort study of patients diagnosed between 2001-2012.

Methods: Acute hepatitis C (AHC) was diagnosed upon detection of high serum ALT (>100 IU) followed by anti-HCV seroconversion. Clinical characteristics, HIV-1-related immunological status and IL-28B genotypes (rs12979860, rs8099917) were collected. We compared these variables between patients with and without spontaneous clearance of HCV and between responders and non-responders to treatment with pegylated interferon (PEG-IFN) plus ribavirin.

Results: Thirty-five patients were diagnosed with AHC during the study period. The majority (96.9%) were MSM. Three were lost to follow-up. Seventy-five percent of patients with AHC (24/32) were asymptomatic and found incidentally to have high serum ALT. Compared to those who did not show spontaneous clearance, patients with spontaneous HCV viral clearance showed more symptoms and more severe abnormalities related to acute hepatitis. Spontaneous clearance was seen in 4 out of 28 patients with CC+TT genotype, but not in 6 patients with IL-28B CT+TG genotype. PEG-IFN plus ribavirin treatment was initiated in 12 out of 28 cases without spontaneous clearance. The sustained virological response rate was high (81.8%, 9/11), even in cases with CT+TG genotype infected with HCV genotype 1b (SVR 2/2).

Conclusions: Careful attention to AHC is needed in HIV-1-infected MSM. Early diagnosis and PEG-IFN plus ribavirin treatment should be considered for AHC cases.

Citing Articles

Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.

Gonzalez S, Fierer D, Talal A Addict Disord Their Treat. 2017; 16(2 Suppl 1):S1-S23.

PMID: 28701904 PMC: 5491232. DOI: 10.1097/ADT.0000000000000104.


Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir.

Hirashima N, Iwase H, Shimada M, Ryuge N, Imamura J, Ikeda H Clin J Gastroenterol. 2016; 10(1):41-46.

PMID: 27766544 DOI: 10.1007/s12328-016-0693-0.


APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.

Omata M, Kanda T, Wei L, Yu M, Chuang W, Ibrahim A Hepatol Int. 2016; 10(5):681-701.

PMID: 27229718 PMC: 5003900. DOI: 10.1007/s12072-016-9736-3.


Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study.

Liu C, Sheng W, Sun H, Hsieh S, Lo Y, Liu C Sci Rep. 2015; 5:17410.

PMID: 26616669 PMC: 4663763. DOI: 10.1038/srep17410.


National Trend and Characteristics of Acute Hepatitis C among HIV-Infected Individuals: A Matched Case-Control Study-Taiwan, 2001-2014.

Lo Y, Tsai M, Sun H, Hung C, Chuang J PLoS One. 2015; 10(10):e0139687.

PMID: 26439381 PMC: 4595084. DOI: 10.1371/journal.pone.0139687.


References
1.
Landau A, Batisse D, Piketty C, Duong van Huyen J, Bloch F, Belec L . Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS. 2001; 15(16):2149-55. DOI: 10.1097/00002030-200111090-00010. View

2.
Piroth L, Larsen C, Binquet C, Alric L, Auperin I, Chaix M . Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study. Hepatology. 2010; 52(6):1915-21. DOI: 10.1002/hep.23959. View

3.
Kamal S, Ismail A, Graham C, He Q, Rasenack J, Peters T . Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology. 2004; 39(6):1721-31. DOI: 10.1002/hep.20266. View

4.
Thomson E, Fleming V, Main J, Klenerman P, Weber J, Eliahoo J . Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut. 2010; 60(6):837-45. PMC: 3095479. DOI: 10.1136/gut.2010.217166. View

5.
Deterding K, Gruner N, Buggisch P, Wiegand J, Galle P, Spengler U . Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis. 2013; 13(6):497-506. DOI: 10.1016/S1473-3099(13)70059-8. View